Stock CLNN CLENE INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Clene Inc.

Equities

CLNN

US1856341029

Real-time Estimate Cboe BZX
Other stock markets
 15:26:05 26/06/2024 BST 		5-day change 1st Jan Change
0.365 USD +1.39% Intraday chart for Clene Inc. -7.98% +21.38%
06-21 Clene Says Lead Drug Candidate Shows Potential to Treat Rett Syndrome MT
06-21 Clene Inc. and Clene Nanomedicine Inc. Present Preliminary Data for CNM-Au8 as Potential Treatment for Rett Syndrome CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Clene to Present at H.C. Wainwright’s 5th Annual Neuro Perspectives Virtual Conference
AQ
Clene Says Lead Drug Candidate Shows Potential to Treat Rett Syndrome
MT
Clene Presents Preliminary Data for CNM-Au8® as a Potential Treatment for Rett Syndrome
AQ
Clene Inc. and Clene Nanomedicine Inc. Present Preliminary Data for CNM-Au8 as Potential Treatment for Rett Syndrome
CI
Clene Presents Extended Survival Data Through 3.5 Years and New NfL Responder Results with CNM-Au8® 30 mg Treatment from the HEALEY ALS Platform Trial Open Label Extension at the 2024 ENCALS Meeting
AQ
Clene Inc. and Clene Nanomedicine, Inc. Present Extended Survival Data Through 3.5 Years and New NfL Responder Results with CNM-Au8 30 mg
CI
Clene to Present at the Emerging Growth Conference
AQ
Clene Inc. Ratifies the Appointment of Deloitte & Touche LLP as Independent Registered Public Accounting Firm for Fiscal Year 2024
CI
Clene Provides Update on Its NIH-Funded Expanded Access Program for CNM-Au8® in ALS (ACT-EAP)
AQ
Clene to Present at Upcoming May Conferences
AQ
Earnings Flash (CLNN) CLENE Reports Q1 Revenue $73M
MT
Clene Reports First Quarter 2024 Financial Results and Recent Operating Highlights
AQ
Clene Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
IBN Announces From Lab to Launch Podcast Featuring Clene Inc. CEO Rob Etherington
AQ
Clene : 2023 Annual Report to Stockholders
PU
Evidence for Clene’s CNM-Au8® as a Treatment for Repair and Remyelination in Multiple Sclerosis Presented in the Emerging Science Session at the 2024 American Academy of Neurology Annual Meeting
AQ
Clene Inc. and Clene Nanomedicine, Inc. Presented the Phase 2 VISIONARY-MS Long term Extension Study Results at the 2024 American Academy of Neurology Annual Meeting in Denver
CI
IBN Announces First in Human Podcast Featuring Clene Inc. CEO Rob Etherington
AQ
Clene Announces Peer-Reviewed Publication Characterizing the Protein Corona of the Investigational Neurodegenerative Disease Drug, CNM-Au8®
AQ
Clene Inc. Announces Peer-Reviewed Publication Characterizing the Protein Corona of the Investigational Neurodegenerative Disease Drug, CNM-Au8
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CLNN Stock
  4. News Clene Inc.